Here, we investigated the expression of Siglec receptors on lung cancer patient-derived MDSCs as well as on myeloid cells from healthy donors (Fig. S1B) by gating on CD33+CD11b+HLA-DRlow/- cells (Fig. S1, A–C). This evidence concerns the gene CD33 and lung carcinoma.